Cutaneous involvement by leukemic cells, consisting of myeloblasts and myeloid cells in varying stages of differentiation, is referred to as myeloid leukemia cutis (LC). 1 Most cases of myeloid LC have been observed in patients with acute myeloid leukemia (AML) or myeloproliferative disorders; however, cutaneous involvement has been reported in patients with myelodysplasia as well. 2 -4 It may also present without prior or concurrent leukemia, referred to as 'aleukemic leukemia cutis'. 5 -7 This presentation provides the greatest diagnostic challenge, requiring careful histologic and cytologic evaluation for myeloid differentiation, coupled with appropriate interpretation of a carefully selected immunohistochemical panel.
Case report
An 87-year-old woman presented with a two-week history of erythematous papules with central crust on her arms, legs and upper chest. She described them as mildly pruritic and denied any prior history of similar lesions. Her past medical history was significant for hypothyroidism and hyperlipidemia. There was no recent change in her medications. Clinically, an arthropod assault or pyoderma gangrenosum was suspected. A 4-mm punch biopsy was performed on a representative lesion from the left anterior thigh.
The biopsy revealed a superficial atypical infiltrate of the papillary and reticular dermis with a predominantly perivascular, but somewhat interstitial distribution pattern (Fig. 1A, B) . A grenz zone was noted above the infiltrate. Cytophagocytosis was focally noted throughout the lesion (Fig 2A, B) . The atypical cells were reactive for lysozyme, CD43, CD68, CD117 and S-100 protein (Fig. 3) . Immunohistochemical stains to CD34, CD1a, myeloperoxidase, CD79a and CD20 were nonreactive in the cells in question. A reactive T-cell population was highlighted with CD3. Special stains for infectious agents, including PAS, GMS and Gram stain, were negative for microorganisms and fungus. Based on the histologic and immunophenotypic features, a diagnosis of myeloid LC was rendered.
Peripheral blood studies, a bone marrow biopsy, flow cytometry and molecular studies were subsequently performed. The patient was found to have a normocytic anemia (hemoglobin 11.1 g/dl; mean corpuscular volume of 88.8 fl) and thrombocytopenia (platelets 89 K/μl). A complete blood count revealed an elevated white blood cell count of 22.21 K/μl with a differential of 36% blasts, 24% neutrophils, 19% monocytes, 10% myelocytes, 5% metamyelocytes, 2% promyelocytes and 1% lymphocytes. The bone marrow biopsy revealed hypercellular bone marrow (80% cellularity) with sheets of immature, atypical and mononuclear cells (Fig. 4) . Four-color flow cytometric immunophenotypic studies revealed a population of myeloid blasts that represented 45% of the analyzed events. Fluorescent in situ hybridization studies for a translocation of the MLL gene on chromosome 11 were negative, and cytogenetic studies showed a normal female karyotype. The histologic, cytogenetic and immunophenotypic characteristics were those of an acute myelomonocytic leukemia.
Discussion
Myeloid LC is the cutaneous involvement of leukemic cells consisting of myeloblasts and other myeloid precursors. Leukemic infiltration of the skin producing a solitary lesion may also be referred to as myeloid sarcoma or extramedullary myeloid tumor. Other terms that have been employed in the past include granulocytic sarcoma, chloroma, myeloblastoma, myelocytoma, granulocytic leukosarcoma and chloromyeloma. 6, 8 The term chloroma originated secondary to the green color occasionally seen on gross examination, attributable to the presence of the intracellular enzyme myeloperoxidase. 9 LC has a diverse range of clinical presentations and may present as erythematous macules, papules, plaques, nodules or ulcerative lesions, with a predilection for the lower extremities followed by the upper extremities, trunk and face. 6, 10, 11 Myeloid LC shows a bimodal age distribution, most commonly occurring in patients younger than 15 years of age and between 45 and 55 years of age. 8 The incidence of cutaneous involvement occurring in association with leukemia has been reported to be 5% to 15% in adults and up to 30% in children. 11 Myeloid leukemia showing monocytic differentiation more frequently involves the skin than other types of myeloid leukemia. 12 Leukemia patients with a t(8;12) chromosomal translocation or numerical abnormalities of chromosome 8, particularly trisomy 8, also appear to have an increased incidence of cutaneous involvement. 3, 6, 13, 14 A de novo occurrence or 'aleukemic leukemia cutis' has been described in which no overt hematologic disorder is evident at presentation. 5, 6 However, most patients presenting with aleukemic leukemia cutis develop AML within 1 year. 15, 16 The histologic features of myeloid LC are variable, and a high index of suspicion is usually necessary to make the correct diagnosis. Helpful diagnostic features are presented in Table 1 . A misdiagnosis rate of up to 75% has been reported in the literature. 17 Most cases are initially given the diagnosis of nonHodgkin lymphoma, mycosis fungoides, metastatic undifferentiated carcinoma, Burkitt lymphoma or large cell lymphoma. 1, 16, 18, 19 The histologic pattern varies depending on the density of the infiltrate. A dense infiltrate usually presents with either a diffuse or nodular and diffuse pattern with frequent extension into the subcutaneous fat. 20, 21 In the setting of a sparse infiltrate, the tumor cells are typically confined to the dermis and are predominantly perivascular or periappendageal in location. 22 Most cases show a well-demarcated grenz zone and absence of epidermal involvement, although one study showed single or multiple foci of intraepidermal spread in more than one-third of cases. 16 However, extensive epidermotropism is usually not appreciated and when present should raise the suspicion of mycosis fungoides. Other histologic features that may be seen in LC include the presence of single tumor cells intercalating between collagen bundles, Langerhans type giant cells, leukemic vasculitis and focal necrosis. 23 -27 Cytologic features evolve along a spectrum according to the degree of maturation of the leukemic cells: differentiated, immature or blastic. Differentiated lesions are composed predominantly of promyelocytes and mature neutrophils, whereas immature lesions are primarily composed of promyelocytes and myeloblasts. Blastic and immature leukemic cell infiltrates often resemble large cell lymphomas. 1 Although the sensitivity is less than 50%, when present, eosinophilic precursors known as eosinophilic myelocytes, characterized by their large violaceous granules, may serve as an important clue to the diagnosis of myeloid LC. 6, 17, 28 Ancillary ultrastructural studies may prove helpful if electron dense granules are present within the tumor. 29 Immunohistochemical analysis is mandatory in the evaluation of LC. CD45 (leukocyte common antigen) is expressed in approximately 90% of 6 
Histology
• Diffuse or nodular and diffuse dermal infiltrate. 23 • Presence of grenz zone. 16, 20, 23 • Frequent extension into the subcutaneous adipose tissue. 20, 21 • Perivascular and/or periappendageal distribution. 22, 23 • Atypical cells infiltrating between collagen fibers. 23, 27 • Focal necrosis, Langerhans' type giant cells and leukemic vasculitis. 24 -26 
Cytology
• Presence of eosinophilic myelocytes (eosinophilic precursors with large eosinophilic and basophilic granules) is a clue to the diagnosis. 6,17,28 • Mitotic figures are usually present. 2 • Varies with leukemic cell differentiation: 1
• Differentiated: variable cell sizes, lobulated nuclei, some cells with eosinophilic granularity.
• Immature: majority of cells with irregular vesicular nuclei and nucleoli.
• Blastic: monotonous, medium to large-sized cells with inconspicuous nuclei, fine powdery chromatin, and scanty cytoplasm. Immunohistochemistry
• CD45 (leukocyte common antigen) positive in 90% of cases. 19 • Lysozyme and CD43 are sensitive markers for myeloid LC.
1,3,4,29,30
• Chloroacetate-esterase and myeloperoxidase stains also sensitive, but more dependent on cellular differentiation. 1 • CD117 (c-Kit) reactivity seen in 85% of myeloid LC. 31 • CD68 may provide utility in more differentiated lesions. 3, 4, 12 • Variable staining with Mac387, CD34 and CD56. 30 
Ultrastructural
• Electron dense granules (most notably ellipsoidal granules) containing axial crystals. 29 cases of myeloid LC, and when positive, helps to exclude non-hematopoietic neoplasms from the differential diagnosis. 19 Ritter et al. compared the immunohistochemical profiles of cases of cutaneous involvement by myeloid leukemia to cases of peripheral T-cell lymphoma and found that CD34 and Mac 387 were specific, but relatively insensitive, markers of LC. 30 Menasce et al. examined 26 cases of extramedullary involvement of myeloid leukemia and found that the staining pattern varied according to the degree of maturation of the neoplastic cells. Chloroacetate-esterase, myeloperoxidase and CD15 were expressed in the majority of welldifferentiated lesions and a smaller proportion of poorly differentiated or blastic lesions. Lysozyme and CD43 were the most sensitive markers with expression in 25 (96%) and 26 (100%) of the cases, respectively. The authors suggested an immunohistochemical panel that included lysozyme, CD43, chloroacetate-esterase and myeloperoxidase, along with B and T lymphocyte markers (CD3 and CD79a or CD20), to confirm the diagnosis of myeloid LC. 1 Others have recommended the addition of CD68, a marker of macrophage origin, and CD117, a transmembrane tyrosine kinase receptor, to this panel when myeloid LC is a diagnostic consideration. 3, 4, 12, 31 The expression of S-100 protein in myeloid LC, as found in our case, has been previously reported in the literature. 29 S-100 protein is a calcium-binding protein which has been detected in a variety of neoplastic and nonneoplastic tissues, including central and peripheral nervous system cells, melanocytes and Langerhans cells. 23 Elliott et al. evaluated 10 cases of myeloid sarcoma for S-100 protein expression, five of which presented as aleukemic leukemia cutis. The authors demonstrated weak to strong S-100 protein immunoreactivity in six cases (6/10). 29 Kaiserling et al. studied 16 skin biopsy specimens with leukemic infiltrates and found the majority expressed S-100 protein. They went on to hypothesize that this expression represented leukemic cells that had undergone differentiation. 23 Cytophagocytosis is a phenomenon of active phagocytosis of leukocytes, erythrocytes and platelets. In the dermatology literature, cytophagocytosis is classically associated with the diagnosis of so-called cytophagic histiocytic panniculitis, now regarded as subcutaneous panniculitis-like T-cell lymphoma (SPTCL), characterized histologically as panniculitis with 'bean bag cells', i.e. large histiocytes containing fragmented leukocytes. 32 Cytophagocytosis by histiocytes appears to be related to the production of cytokines, particularly interferons and macrophage inflammatory protein 1α, produced by endothelial cells, lymphocytes and macrophages themselves. The phagocytic nature shown by blast cells in AMLs might be explained by the 'monocytic' differentiation of the cell population; this hypothesis is supported by the increased association of this finding in AML of the myelomonocytic and monocytic types. 33 In addition, the presence of cytophagocytosis by blast cells in AMLs has also been shown to have prognostic significance. Liso et al. evaluated bone marrow and peripheral blood smears of 1138 cases of AML for the presence of cytophagocytosis. One percent of the AML cases showed cytophagocytosis, and these patients had poor clinical outcomes, including diminished responses to therapy and shorter survival times, in comparison to those cases without this histologic feature. 33, 34 These findings suggest that the presence of cytophagocytosis may provide prognostic relevance in addition to aiding in the diagnosis of malignancy.
The combination of cytophagocytosis and S-100 protein reactive cells may generate the consideration of Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy) within the differential diagnosis. Cutaneous involvement of Rosai-Dorfman disease is characterized by foamy histiocytes, some of which show emperipolesis, in a background of a dense mixed infiltrate consisting of lymphocytes, plasma cells and neutrophils. Emperipolesis differs from cytophagocytosis in that the phagocytosed cells are not digested by enzymes and are morphologically well preserved within the histiocytes. In addition, the characteristic histiocytic cells show diffuse, strong cytoplasmic and nuclear staining for S-100 protein. CD68 and lysozyme have been shown in a percentage of Rosai-Dorfman cells as well. 35 However, a pure cutaneous involvement of Rosai-Dorfman disease is rare as most patients have evidence of systemic involvement, facilitating in the differentiation from LC.
The prognosis of patients with myeloid LC has been shown to correlate with the initial presentation. The overall outcome in patients with AML prior to the development of LC does not appear adversely impacted by a subsequent diagnosis of LC. However, patients without AML at the time of diagnosis of LC tend to have a worse prognosis. 6 In addition, correct initial diagnosis of LC at presentation has been found to impact patient prognosis. Mansi et al. found that patients diagnosed correctly at the time of presentation and treated with AML protocols had remissions lasting from 2 to 166 months, whereas patients initially misdiagnosed were less likely to have a period of remission. 36 In conclusion, myeloid LC can be a difficult diagnosis when associated with an aleukemic presentation and unexpected histologic and immunohistochemical findings. The diagnosis of LC is often made in retrospect once leukemia becomes present clinically. Careful evaluation of clinical, gross and histologic findings along with employment of an appropriate immunohistochemical panel may aide in the correct diagnosis of LC at the time of initial presentation.
